Last reviewed · How we verify
HBM4003 and Triprilimab
At a glance
| Generic name | HBM4003 and Triprilimab |
|---|---|
| Also known as | HBM4003 |
| Sponsor | Harbour BioMed (Guangzhou) Co. Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 Combine With Toripalimab in Patients With Advanced HCC and Other Solid Tumors (PHASE1)
- Study Investigating Safety,Tolerability,Pharmacokinetics and Antitumor Activities of HBM4003 Combine With Toripalimab (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HBM4003 and Triprilimab CI brief — competitive landscape report
- HBM4003 and Triprilimab updates RSS · CI watch RSS
- Harbour BioMed (Guangzhou) Co. Ltd. portfolio CI